Scott Glenn

Board Member

Mr. Glenn currently serves as the Managing Partner of Windamere Venture Partners, LLC and is one of the founding members of Precision IBD, the predecessor of Prometheus Biosciences. He has founded over twenty successful biotech companies and has over twenty-five years of experience as Chairman/CEO and founder of Quidel, Prometheus Labs, DexCom, Santarus, Kanisa, Exagen Diagnostics, Oncternal and Alastin Skincare. Mr. Glenn is also founder of SpineWave Zogenix, Cadence Pharmaceuticals, NovaCardia, SkinMedica, Conception Technologies and Somaxon. Mr. Glenn also held various management positions, including Division General Manager with Allergan, Inc.